Eribulin for the treatment of advanced breast cancer: A prospective observational registry study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Cancer Care"
DOI: 10.1111/ecc.13747
Abstract: Abstract Objective Eribulin treatment improved overall survival with predictable toxicities in phase 3 trials of patients with previously treated, locally advanced/metastatic breast cancer. This study (NCT02443428) prospectively observed eribulin‐treated patients in real‐world clinical practice. Methods… read more here.
Keywords: eribulin treatment; breast cancer; cancer; registry study ... See more keywords
Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Oncology"
DOI: 10.1159/000526140
Abstract: Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from patients with MBC who had… read more here.
Keywords: eribulin treatment; breast cancer; metastatic breast; treatment ... See more keywords
Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting
Sign Up to like & getrecommendations! Published in 2022 at "Chemotherapy"
DOI: 10.1159/000526490
Abstract: Background: This study aimed to examine the effectiveness and safety of eribulin used as an early-line (EL, i.e., first-/second-line) versus late-line (LL, i.e., third-line and beyond) chemotherapy for recurrent advanced or metastatic breast cancer (A/MBC)… read more here.
Keywords: eribulin treatment; group; breast cancer; metastatic breast ... See more keywords
Utility of Follow-up With Absolute Lymphocyte Count in Patients Undergoing Eribulin Treatment for Early Detection of Progressive Advanced or Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15553
Abstract: Background/Aim: Eribulin, a non-taxane microtubule inhibitor, improves the tumor immune microenvironment via vascular remodeling. Systemic peripheral immune markers such as absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) have been reported as prognostic factors of… read more here.
Keywords: eribulin treatment; absolute lymphocyte; treatment; alc ... See more keywords
Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15858
Abstract: Background/Aim: Eribulin is an effective chemotherapeutic agent for the treatment of metastatic breast cancer and advanced or metastatic soft-tissue sarcomas. However, severe adverse effects (SAEs) occur in 30-40% of the patients, and significantly reduce the… read more here.
Keywords: eribulin treatment; risk factors; occurrence; treatment ... See more keywords